Previous 10 | Next 10 |
3 Hot Penny Stocks to Watch This Week With a new week in August upon us, which penny stocks are investors watching? Well, to understand this we have to take into consideration what’s going on in the world. Right now, this includes the highly positive jobs report that came out las...
Mustang Bio (NASDAQ:MBIO) announces that the European Medicines Agency (EMA) has granted Priority Medicines (“PRIME”) designation to MB-107 for the treatment of X-linked severe combined immunodeficiency (“XSCID”) in newly diagnosed infants, also known as bubble boy...
WORCESTER, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
The following slide deck was published by Mustang Bio, Inc. in conjunction with this event. For further details see: Mustang Bio (MBIO) EHA Investor Presentations - Slideshow
WORCESTER, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
4 Penny Stocks To Watch This Week With Upcoming Events Penny stocks can be fickle. On the one hand, many will move with different market trends. On the other hand, they may be completely disconnected from broader sentiment. This month, we’ve seen both of these instances, with eve...
Mustang Bio (MBIO) announces updated interim data from Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 CD20-targeted, autologous CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia ((CLL)).MBIO shares rise 7% pre...
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in patients treated with modified cell manufacturing process Key opinion lead...
Webinar to be held Tuesday, June 15, 2021, at 1:00 p.m. ET WORCESTER, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficul...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...